The system
How the system worksThe DirectoryDispatchThe LedgerAI modelsAI agentsYour installationThe appThe research libraryWhat changes for your businessUse it from your softwareEverything it can do
Messaging
iMessageWhatsApp
Ads and leads
AdsCreativeLeads
Devices
Devices
Industries
RealtorsRestaurantsHome services
Explore
How it worksPermissions and limitsCompareSet upQuestionsText me

Semax for Statin-Associated Cognitive Effects

Post-marketing surveillance has documented rare reports of cognitive impairment including memory loss, forgetfulness, amnesia, confusion associated with statin use across all statins (mechanistic). These reports are generally described as

Statin-Associated Cognitive Reports

Post-marketing surveillance has documented rare reports of cognitive impairment including memory loss, forgetfulness, amnesia, confusion associated with statin use across all statins (mechanistic). These reports are generally described as non-serious and reversible upon discontinuation.

Large-scale reviews and meta-analyses of randomized controlled trials have found no consistent signal of cognitive impairment with statins and in some cases suggest possible protective effects against dementia (human).

One analysis of acute memory loss found a strong association in the first 30 days after statin initiation compared to non-users but not versus non-statin lipid-lowering drugs (human).

Mechanistic hypotheses include potential disruption of brain cholesterol synthesis, which may affect cognitive function in sensitive individuals (mechanistic).

Semax and BDNF

In rat hippocampus, a single intranasal dose of Semax increased BDNF protein levels 1.4-fold, trkB phosphorylation 1.6-fold, and exon III BDNF mRNA 3-fold, accompanied by improved conditioned avoidance responses (preclinical).

Semax is described as upregulating BDNF for neuroprotection and cognitive recovery (mechanistic).

Human clinical data on Semax are limited to contexts such as ischemic stroke recovery with some reports of improved neurological outcomes; no human trials examine Semax in statin users or for statin-associated cognitive effects (human).

No direct human data exist linking Semax to mitigation of statin-related cognitive reports.

Mapping and Novelty

Semax's documented BDNF upregulation in preclinical models provides a mechanistic rationale for supporting neural repair pathways, distinct from suppression approaches (mechanistic).

Direct evidence in statin users is absent; the application remains speculative with high novelty due to lack of targeted studies (speculative).

---

Related: Semax

source_ledger· 3,540 words
Semax: a Russian stroke drug sold as a focus spray, and what its numbers actually show
Semax is a seven-amino-acid peptide that has been a registered medicine in Russia since the early 1990s, given in hospitals after a stroke and after a head injury. It is sold in the United States as a nose spray or a vial of powder, and
converted from
markdown
original updated
2026-08-04T21:15:51.241Z
register
source_ledger
category
null
References (4)
  1. Statins and Brain Fog: Confusing for Patients, Prescribers, and Me“There have been rare post-marketing reports of cognitive impairment (e.g.,memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use.”
  2. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus“a single application of Semax (50 microg/kg body weight) results in a maximal 1.4-fold increase of BDNF protein levels... 3-fold and a 2-fold increase of exon III BDNF and trkB mRNA levels, respectively, in the rat hippocampus.”
  3. Statins and Memory Loss: Is There a Link?“Current research does not demonstrate a definitive connection between statin use and memory loss, and some studies suggest statins may even have a protective effect against dementia.”
  4. Semax: The Neuroprotective Peptide Changing Cognitive Research“In a randomized controlled trial (Gusev et al., Cerebrovascular Diseases, 2005), Semax administered intranasally in the acute phase was associated with reduced neurological deficit scores...”